Trovagene Eyes $6.1M in Public Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Trovagene said in a regulatory filing on Wednesday that it is publicly offering $6.1 million of its common stock.

In total, the company plans on offering more than 1.2 million shares, which will be issued upon the exercise of outstanding warrants that Trovagene issued in mid-2012 as part of a public offering when the company moved to the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.